BPGbio Reports Encouraging Preliminary Data from Ongoing Phase 2 Study of BPM31510 in Newly Diagnosed Glioblastoma

Phase 2positiveBPM31510Positive

AI Analysis

Summary

BPGbio reported encouraging preliminary data from an ongoing Phase 2 study of BPM31510, a mitochondrial-targeted therapy, combined with standard-of-care treatment in newly diagnosed glioblastoma patients. The data were presented at the 2026 ASCO Annual Meeting.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Encouraging preliminary data from Phase 2 study of BPM31510 in combination with radiation therapy and temozolomide in newly diagnosed glioblastoma

Importance:6/10

Sentiment:

0.65

oncologyglioblastomamitochondrial therapyclinical trialcombination therapyASCO 2026

Related Companies

$ATALF $DFPH

Read the original article

Published by GlobeNewswire Clinical Studies on July 15, 2026 11:00 AM

Read Original